158 related articles for article (PubMed ID: 10393535)
1. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
2. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
3. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
[TBL] [Abstract][Full Text] [Related]
4. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
5. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
6. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
[TBL] [Abstract][Full Text] [Related]
7. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
8. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
9. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
Lin JH; Castora FJ
Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin.
Madden KR; Champoux JJ
Cancer Res; 1992 Feb; 52(3):525-32. PubMed ID: 1310066
[TBL] [Abstract][Full Text] [Related]
11. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines.
Beidler DR; Chang JY; Zhou BS; Cheng YC
Cancer Res; 1996 Jan; 56(2):345-53. PubMed ID: 8542590
[TBL] [Abstract][Full Text] [Related]
12. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110.
Yoshinari T; Yamada A; Uemura D; Nomura K; Arakawa H; Kojiri K; Yoshida E; Suda H; Okura A
Cancer Res; 1993 Feb; 53(3):490-4. PubMed ID: 8381047
[TBL] [Abstract][Full Text] [Related]
13. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin.
Bjornsti MA; Benedetti P; Viglianti GA; Wang JC
Cancer Res; 1989 Nov; 49(22):6318-23. PubMed ID: 2553253
[TBL] [Abstract][Full Text] [Related]
14. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Fujimori A; Harker WG; Kohlhagen G; Hoki Y; Pommier Y
Cancer Res; 1995 Mar; 55(6):1339-46. PubMed ID: 7882333
[TBL] [Abstract][Full Text] [Related]
15. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
[TBL] [Abstract][Full Text] [Related]
16. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
Eng WK; Faucette L; Johnson RK; Sternglanz R
Mol Pharmacol; 1988 Dec; 34(6):755-60. PubMed ID: 2849043
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne.
Wang LK; Rogers BD; Hecht SM
Chem Res Toxicol; 1996; 9(1):75-83. PubMed ID: 8924619
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
Jaxel C; Kohn KW; Wani MC; Wall ME; Pommier Y
Cancer Res; 1989 Mar; 49(6):1465-9. PubMed ID: 2538227
[TBL] [Abstract][Full Text] [Related]
19. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Fujimori A; Gupta M; Hoki Y; Pommier Y
Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
[TBL] [Abstract][Full Text] [Related]
20. The dihydropyridine dexniguldipine hydrochloride inhibits cleavage and religation reactions of eukaryotic DNA topoisomerase I.
Straub T; Boesenberg C; Gekeler V; Boege F
Biochemistry; 1997 Sep; 36(35):10777-83. PubMed ID: 9271509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]